FBDD Fragments Base Drugs Discovery | Design
   
               
Search    
18-Jul-2014
  IOTA publishes review with Genentech scientists describing the use of mechanism-informed phenotypic screening (MIPS) in oncology drug discovery
   
2-Apr-2014
  IOTA Pharmaceuticals in €7.8M consortium tackling neglected parasitic diseases
   
21-Sep-2012
  IOTA InFarmatik Press Release
   
22-Feb-2011
  IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011
   
17-Aug-2009
  New consortium to develop drugs for neglected tropical diseases
   
23-Apr-2008
  IOTA announces SPR initiative with Beactica AB
   
21-Dec-2007
  IOTA announces FBDD screening services
   
21-Dec-2007
  IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000
   
5-Aug-2007
  IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.
   
3-Aug-2007
  IOTA announces FBDD Initiative with the VU University, Amsterdam
   
25-Sep-2007
  IOTA announces first FBDD product: IOTA Diverse 1500
   
 
 
Through its co-Founder, Dr Paul England, IOTA has considerable experience in high-sensitivity, high-throughput compound screening, both at the biochemical and functional, cell-based level.
 
IOTA’s main experimental labs are based in the Vrije Universiteit in Amsterdam. Long a centre of excellence for GPCR pharmacology, the University has developed state-of-the-art compound screening facilities, and has the capability of running screens for many different molecular targets in several different formats (fluorescence, NMR, MS, etc).
 
 
 
 
 
IOTA Fragment Screening Services
ProteasesKinases GPCRs
Chemokine Receptors Nuclear Hormone Receptors Nicotinic Receptors
Copyright © 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms